title: Intravesical heparin and peripheral neuromodulation on interstitial cystitis.
abstract: BACKGROUND
  We wanted to evaluate the therapeutic effect of intravesical heparin and peripheral neuromodulation on patients with interstitial cystitis.
  
  
  METHODS
  From March 2002 to August 2003, 8 female and 2 male subjects conform to the NIDDK criteria and not responsive to the previous conventional treatments were included in the study. Wisconsin pain scores, maximal cystometric capacities, and night and day voiding frequencies were determined and these studies were repeated in the 2nd and 12th months of the treatment with 10,000 units intravesical heparin and peripheral neuromodulation. Frequency of the treatment was once a week during first 8 weeks, once in 2 weeks in the following 8 weeks, and once in 3 weeks four times. Then, it was decreased to once a month.
  
  
  RESULTS
  The mean follow-up period was 13 months (12-16 months). Day and night voiding frequency were significantly better in the 2nd and 12th months, when compared to pretreatment values. The Wisconsin pain scores were 62.5 +/- 13.9% and 62.8 +/- 15.2% in the 2nd and the 12th months, respectively. The average increase in the maximum cystometric capacity was 54.8 +/- 27.4% and 52.5 +/- 31.6% in the 2nd and the 12th months, respectively.
  
  
  CONCLUSIONS
  Intravesical heparin and peripheral neuromodulation combination seems to be an alternative for patients with interstitial cystitis not responsive to other treatments.
authors.affiliation: GATA Haydarpaşa Training Hospital, Department of Urology, Uskudar/Istanbul, Turkey.
authors.forename: Kadir
authors.initials: K
authors.lastname: Baykal
authors.forename: Temuçin
authors.initials: T
authors.lastname: Senkul
authors.forename: Bulent
authors.initials: B
authors.lastname: Sen
authors.forename: Kenan
authors.initials: K
authors.lastname: Karademir
authors.forename: Cuneyt
authors.initials: C
authors.lastname: Adayener
authors.forename: Dogan
authors.initials: D
authors.lastname: Erden
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D018856:Cystitis, Interstitial / Q000150:complications / Q000628:therapy*; D019610:Cytoprotection / Q000187:drug effects; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013979:Tibial Nerve; D004561:Transcutaneous Electric Nerve Stimulation / Q000379:methods*; D016896:Treatment Outcome; D014555:Urination Disorders / Q000209:etiology / Q000628:therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D006493:Heparin